Skip to main content
TipRanks
Go Ultimate75% OFF

Noxopharm Ltd. (NOX) Share Price & Analysis

3 Followers

NOX Stock Chart & Stats

A$0.04A$0.00(5.71%)
At close: 4:00 PM GMT+11
AU$0.04AU$0.06AU$0.08Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.04 - AUD 0.04
52-Week Range
AUD 0.03 - AUD 0.11
Previous Close
AUD 0.04
Volume
N/A
Average Volume (3M)
200.81K
Market Cap
AUD 12.36M
Enterprise Value
AUD 30.46M
Total Cash (Recent Filing)
AUD 293.57K
Total Debt (Recent Filing)
AUD 4.57M
Price to Earnings (P/E)
―
Beta
1.22
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Oncology Pipeline

A focused oncology and immuno-oncology strategy gives Noxopharm a clearly defined therapeutic area and the potential to build value around specialized drug candidates. Progressing assets through preclinical and clinical development, including combination approaches, supports a coherent long-term R&D platform.

Narrower Operating Losses

The material reduction in operating losses suggests improved cost control or lower expense intensity, which could moderate the rate of resource consumption. Although profitability remains distant, maintaining this improvement would strengthen operating discipline and extend the company’s ability to advance its development programs.

Improved Cash-burn Trend

A substantially smaller operating cash outflow is a constructive change in the company’s funding profile, even though cash generation remains negative. If sustained, lower burn would lengthen available financial capacity and allow more capital to remain focused on advancing oncology research and development.

Bears Say

Negative Equity And Rising Debt

Negative stockholders’ equity indicates that accumulated losses or capital structure strain have materially weakened the balance sheet. Rising debt further reduces financial flexibility, increases pressure to secure funding, and makes it harder to sustain development spending without additional capital support.

Persistent Losses And Revenue Contraction

Continued operating and net losses show that the business has not yet reached a self-sustaining earnings model. The sharp revenue contraction also limits operating leverage, making it harder for fixed development activities to be supported by internal revenue over the next several quarters.

Ongoing Dependence On External Financing

Persistent operating and free-cash-flow outflows mean Noxopharm cannot currently fund its activities from internally generated cash. Continued reliance on external financing exposes the development program to funding availability and can constrain strategic flexibility if capital becomes harder to obtain.

Noxopharm Ltd. News

NOX FAQ

What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$12.36M.
When is Noxopharm Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is Noxopharm Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 334,091,500 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology